WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 5, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
will host an analyst and institutional investor meeting on Tuesday,
March 24, 2015, in New York City from 8:00 a.m. to approximately 10:00
a.m. Eastern Time. The meeting will include remarks from the AtriCure
management team highlighting the company’s strategy for executing on its
growth initiatives as well as guest speakers to provide clinical
James L. Cox, M.D., cardiothoracic surgeon and developer of the
Cox-Maze procedure for the surgical treatment of atrial fibrillation.
Jonathan Philpott, M.D., cardiothoracic surgeon and Director of
the Sentara Atrial Fibrillation Surgery Program at Sentra Heart
S. Patrick Whalen, M.D., FHRS, electrophysiologist and
Associate Professor of Medicine at Wake Forest Baptist Health.
A live audio webcast and replay of the meeting will be available for 30
days following the meeting on the Investors page of AtriCure’s corporate
website at www.atricure.com.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of Persistent and Longstanding Persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip Left Atrial Appendage Management (LAAM) exclusion
device is the most widely sold device worldwide that’s indicated for the
occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. Afib affects more than 33.5 million people worldwide.
Source: AtriCure, Inc.
Andy Wade, 513-755-4564
Vice President and Chief Financial Officer